Advanced search
Publication Cover
Drug and Chemical Toxicology Volume 47, 2024 - Issue 1
Submit an article Journal homepage
165
Views
1
CrossRef citations to date
0
Altmetric
Research Articles

Two cases report of febuxostat-induced acute liver injury: acute heart failure as a probable risk factor?

Bolin Zhua Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, P. R. ChinaView further author information
,
Bing Liub Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaView further author information
,
Guodong Tangb Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaView further author information
,
Pengfei Jina Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, P. R. ChinaView further author information
&
Deping Liub Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaCorrespondence[email protected]
View further author information
Pages 55-59 | Received 27 Oct 2022, Accepted 03 Feb 2023, Published online: 14 Feb 2023

References

  • Bohm, M., Vuppalanchi, R., and Chalasani, N, Drug-Induced Liver Injury Network (DILIN), 2016. Febuxostat-induced acute liver injury. Hepatology, 63 (3), 1047–1049.
  • Chalasani, N., et al., United States Drug Induced Liver Injury Network, 2015. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology, 148 (7), 1340–1352.e7.
  • Chalasani, N.P., Practice Parameters Committee of the American College of Gastroenterology, et al., 2014. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. The American Journal of Gastroenterology, 109 (7), 950–966; quiz 967.
  • Farmer, A.D. and Brind, A., 2011. Drug-induced liver injury. Medicine, 39 (9), 536–540.
  • FDA. 2019. FDA adds boxed warning for increased risk of death with gout medicine uloric (febuxostat). FDA Drug Safety Podcast Web site. Available from: https://www.fda.gov/drugs/fda-drug-safetypodcasts/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat.Published.
  • Gonzalez, A.K., and Lefkowitch, J.H., 2017. Heart disease and the liver: pathologic evaluation. Gastroenterology Clinics of North America, 46 (2), 421–435.
  • Hayashi, P.H., and Fontana, R.J., 2014. Clinical features, diagnosis, and natural history of drug-induced liver injury. Seminars in Liver Disease, 34 (2), 134–144.
  • Ito, K., et al., 2014. Acute severe liver dysfunction induced by febuxostat in a patient undergoing hemodialysis. CEN Case Reports, 3 (2), 158–161.
  • Lee, J.S., et al., 2019. Hepatic safety of febuxostat compared with allopurinol in gout patients with fatty liver disease. The Journal of Rheumatology, 46 (5), 527–531.
  • Leise, M.D., Poterucha, J.J., and Talwalkar, J.A., 2014. Drug-induced liver injury. Mayo Clinic Proceedings, 89 (1), 95–106.
  • Mackenzie, I.S., et al., 2020. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. The Lancet, 396 (10264), 1745–1757.
  • Radovanovic, M., et al., 2018. Idiosyncratic drug-induced liver injury due to ciprofloxacin: A report of two cases and review of the literature. American Journal of Case Reports, 19, 1152–1161.
  • Watkins, P.B., 2011. Drug safety sciences and the bottleneck in drug development. Clinical Pharmacology and Therapeutics, 89 (6), 788–790.
  • White, W.B., et al., 2018. Cardiovascular safety of febuxostat or allopurinol in patients with gout. New England Journal of Medicine, 378 (13), 1200–1210.
  • Xanthopoulos, A., et al., 2019. Heart failure and liver disease: cardiohepatic interactions. JACC, 7 (2), 87–97.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.